Precigen (PGEN)
(Real Time Quote from BATS)
$1.01 USD
-0.06 (-5.61%)
Updated Sep 20, 2024 10:22 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
PGEN 1.01 -0.06(-5.61%)
Will PGEN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PGEN
Precigen, Inc. (PGEN) Reports Q2 Loss, Misses Revenue Estimates
Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
PGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
Insulet (PODD) Q2 Earnings Miss Estimates
Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline
Other News for PGEN
Precigen to Participate in the 2024 Cantor Global Healthcare Conference
Precigen Aligns Executive Incentives with FDA Approval Goals
Biotech Alert: Searches spiking for these stocks today
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Buy Rating Affirmed for Precigen Amid Promising PRGN-2012 Clinical Data and Strategic Focus